An observational study in Myeloproliferative Neoplasm, Myeloproliferative Syndrome and Myeloproliferative Neoplasm, Unclassifiable, sponsored by Sociedad de Lucha Contra el Cáncer del Ecuador. Completed at 1 site in Ecuador. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-27.
Sponsored by Sociedad de Lucha Contra el Cáncer del Ecuador · Observational
The goal of this observational study is to evaluate the epidemiological and clinical-pathological features of Philadelphia-negative myeloproliferative neoplasms through data from medical records
The investigators are proposing a study that provides descriptive understanding of patients with Philadelphia-negative myeloproliferative neoplasms in Ecuador. The primary objective of this pilot study is to lay the foundations for the development of a multicenter registry of Philadelphia-negative myeloproliferative neoplasms, which will provide high-quality real data and serve as a basis for the application to future projects and elaboration of public policies in the medium and long term.
667 studies on the registry are indexed under Myeloproliferative Disorders; 110 are open to participants now.
This study's enrollment of 40 is below the median of 150 across 115 observational studies indexed under Myeloproliferative Disorders.
Browse Myeloproliferative Disorders studies →Sociedad de Lucha Contra el Cáncer del Ecuador is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with Philadelphia-negative Myeloproliferative Neoplasms according to the 2022 World Health Organization (WHO) classification
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Number of patients with Philadelphia-negative Myeloproliferative Neoplasms in Ecuador
Participants were followed-up for 8 years. This is the number of participants who have had Philadelphia-negative Myeloproliferative Neoplasms in Ecuador during the time of observation.
Time frame: 96 months
Prevalence of Philadelphia-negative myeloproliferative patients
Calculation of the prevalence of participants who have had Philadelphia-negative Myeloproliferative Neoplasms in Ecuador during the time of observation.
Time frame: 96 months
Mortality risk as measured by the Dynamic International Prognostic Scoring System
The Dynamic International Prognostic Scoring System (DIPSS) was proposed and validated by Passamonti and is used as a prognostic model to predict survival in participants with Primary Myeloid Fibrosis a Philadelphia-negative myeloproliferative neoplasm. Possible scores range from 0 to 6, with higher scores indicating higher mortality risk.
Time frame: 96 months
Overall survival
Percent of participants with Primary Myeloid Fibrosis who were alive at 96 months of follow-up
Time frame: 96 months
Plan to share: Undecided
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myeloproliferative Disorders →
Sociedad de Lucha Contra el Cáncer del Ecuador